FMR LLC reports 3.9% stake in Cytokinetics

FMR LLC reports beneficial ownership of 5,248,579.71 shares of Cytokinetics Inc. Common Stock, representing 3.9% of the class as of 06/30/2026.

Rhea-AI Filing Summary

FMR LLC reports beneficial ownership of 5,248,579.71 shares of Cytokinetics Inc. Common Stock, representing 3.9% of the class as of 06/30/2026. The filing (Amendment No. 8 to Schedule 13G/A) lists sole dispositive power for 5,248,579.71 shares and sole voting power of 5,220,899.42 shares. The report notes that one or more other persons may have rights to dividends or sale proceeds but that no other person holds more than 5% of the outstanding common stock. The filing is signed under a power of attorney and references an exhibit for a 13d-1(k)(1) agreement.

Insights

Institutional Ownership Analyst

FMR LLC holds a 3.9% stake in CYTK as of 06/30/2026.

FMR LLC is disclosed as beneficial owner of 5,248,579.71 shares with sole dispositive power and near-complete sole voting power reported. The schedule is an ownership disclosure under Schedules 13G/A and does not indicate an active transaction.

Cash-flow treatment and any intent to sell or acquire additional shares are not stated in the excerpt; subsequent filings would show changes in position.

Compliance & SEC Filings Specialist

Amendment No. 8 updates beneficial-ownership particulars and attaches a power-of-attorney reference.

The filing includes a signature by an authorized representative under a power of attorney effective April 13, 2026, and references Exhibit 99 for a 13d-1(k)(1) agreement. It follows Schedule 13G/A disclosure protocols for institutional holders.

Ownership percentages, share counts, and voting/dispositive powers are explicitly stated in the filing text and anchored to 06/30/2026.

Key Figures

Beneficial ownership: 5,248,579.71 shares Percent of class: 3.9% Sole voting power: 5,220,899.42 shares +1 more

4 metrics

Beneficial ownership 5,248,579.71 shares as of 06/30/2026

Percent of class 3.9% Common stock ownership percentage

Sole voting power 5,220,899.42 shares reported on cover page

Sole dispositive power 5,248,579.71 shares reported on cover page

Key Terms

Schedule 13G/A, Beneficial ownership, Dispositive power, 13d-1(k)(1) agreement

4 terms

Schedule 13G/A regulatory

"Amendment No. 8 to Schedule 13G/A (ownership disclosure)"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficial ownership financial

"Item 4. Ownership (a) Amount beneficially owned: 5248579.71"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Dispositive power regulatory

"Sole Dispositive Power 5,248,579.71"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

13d-1(k)(1) agreement regulatory

"Please see Exhibit 99 for 13d-1(k) (1) agreement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does FMR LLC report in CYTK?

FMR LLC reports beneficial ownership of 5,248,579.71 shares, representing 3.9% of Cytokinetics' common stock as of 06/30/2026. The filing lists sole dispositive power for the same share count.

Does FMR LLC have voting power over the reported CYTK shares?

Yes. The filing shows FMR LLC has sole voting power for 5,220,899.42 shares, with 0.00 shared voting power reported in the cover data.

Is another party listed as holding more than 5% of CYTK?

No. The filing states that one or more other persons may have rights to dividends or proceeds, but no other person's interest exceeds 5% of the outstanding common stock.

What exhibits or authorities are referenced in this Schedule 13G/A amendment?

The amendment refers to a power of attorney effective April 13, 2026 and to Exhibit 99 for a 13d-1(k)(1) agreement; the signature block cites an incorporated Exhibit 24 filing from April 29, 2026.

Does this filing indicate that FMR LLC bought or sold CYTK shares?

No. This Schedule 13G/A amendment discloses beneficial ownership and voting/dispositive powers; it does not state any purchase or sale transactions in the provided excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 10:11 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 8)

CYTOKINETICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

23282W605

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 23282W605

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,220,899.42
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,248,579.71
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,248,579.71

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.9 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): 23282W605

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,248,579.71
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,248,579.71

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.9 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CYTOKINETICS INC
(b)	Address of issuer's principal executive offices: 350 OYSTER POINT BOULEVARD,South San Francisco,CA,USA,94080
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 23282W605
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5248579.71
(b)	Percent of class: 3.9 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 5248579.71
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of CYTOKINETICS INC. No one other person's interest in the COMMON STOCK of CYTOKINETICS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	07/07/2026

Abigail P. Johnson

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of Abigail P. Johnson*
Date:	07/07/2026

Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on April 29,2026, accession number: 0000315066-26-000738.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.